Cart
sales@molnova.com
CGP 35949
CAS No. 111130-13-3
CGP 35949( —— )
Catalog No. M34546 CAS No. 111130-13-3
CGP 35949 is an LTD4 antagonist with phospholipase inhibitory activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 255 | Get Quote |
|
| 10MG | 375 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 762 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2043 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCGP 35949
-
NoteResearch use only, not for human use.
-
Brief DescriptionCGP 35949 is an LTD4 antagonist with phospholipase inhibitory activity.
-
DescriptionCGP-35949 sodium is a LTD4 antagonist with phospholipase inhibitory activity. CGP-35949 sodium can be used for research of asthma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetLeukotriene Receptor
-
RecptorLeukotriene Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number111130-13-3
-
Formula Weight509.92
-
Molecular FormulaC23H25ClN5NaO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCC1=C(OCCCOC2=C(Cl)C=C(C)C(NC(C3=NN=N[N-]3)=O)=C2)C=CC(C(C)=O)=C1O.[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Beck A, et al. CGP 35949, an LTD4 antagonist with phospholipase inhibitory activity: a new approach to the treatment of asthma. Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:771-4.?
molnova catalog
related products
-
SR 2640 hydrochlorid...
SR 2640 hydrochloride is a competitive antagonist of leukotriene D4 and E4 and can be used in studies about leukotrienes in human asthma.
-
Masilukast
Masilukast(MCC-847) is an oral leukotriene D4 (LTD4) receptor antagonist for the study of diseases associated with inflammation.
-
Pobilukast
Pobilukast (SKF 104353) is a selective cysteinyl leukotriene receptor antagonist that blocks phosphatidylinositol metabolism and leukotriene D-induced thromboxane synthesis, and can be used to study limiting myocardial damage in excessively myocardial reperfusion-injured (MI/R) rats.
